Fierce Biotech1 min read
saveValneva sees LimmaTech vaccine reduce Shigella infections in phase 2 test
Valneva’s Shigella vaccine has been shown to reduce cases of intestinal infection, hitting the key endpoint of a phase 2 trial.
Valneva’s Shigella vaccine has been shown to reduce cases of intestinal infection, hitting the key endpoint of a phase 2 trial.
comments(0)
5-min edit window · permanent after that